Fresenius Vamed - A Polyclinic in Ghana
At Fresenius, we are at the heart of healthcare. For all our activities, our patients take center stage. We focus on world-class therapies, which we continuously improve to keep pace with the major trends in healthcare. Our therapy focus is reflected in three platforms:
(Bio)Pharma
Biosimilars
IV Generics and Fluids
Clinical Nutrition
MedTech
Infusion and Nutrition Systems
Transfusion Medicine and Cell Therapies
Care Provision
Inpatient and Outpatient Treatments
Occupational Healthcare and Prevention
Reproductive Medicine
Furthermore, our Investment Company Fresenius Vamed expands our offering to:
Project Business and Services
Rehabilitation, Care and Health Tourism
An open dialog with our shareholders and the financial community is important to us. The Fresenius Investor Relations team will be happy to answer all your questions and inquiries.
Fresenius SE & Co. KGaA
Investor Relations
Else-Kröner-Str. 1
D-61352 Bad Homburg
Germany
ir-fre@fresenius.com
Postal address:
Fresenius SE & Co. KGaA
Investor Relations
D-61346 Bad Homburg v.d.H.
Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
Karen Janek
Assistant Investor Relations
T: +49 (0) 6172 608-2487
karen.janek@fresenius.com
Silke Zimmermann
Assistentin Investor Relations
T: +49 (0) 6172 608-2464
silke.zimmermann@fresenius.com
Florian Feick
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Stefanie Drees
Director Investor Relations
T: +49 (0) 6172 608-5211
stefanie.drees@fresenius.com
Michael Otto
Director Investor Relations
T: +49 (0) 6172 608-2419
michael.otto@fresenius.com
Elisabeth Truckenbrodt
Director Investor Relations
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com
Felix Klein
Senior Manager Investor Relations
T: +49 (0) 6172 608-96484
felix.klein@fresenius.com
Mara Sinsel
Senior Manager Investor Relations
T: +49 (0) 6172 608-96538
mara.sinsel@fresenius.com
Annette Hainz
Manager Investor Relations
T: +49 (0) 6172 608-2604
annette.hainz@fresenius.com
Elisabeth Jung
Manager Investor Relations
T: +49 (0) 6172 608-2419
elisabeth.jung@fresenius.com
Bonds
| Issuer | Volume in million | Coupon | Maturity |
|---|---|---|---|
| €500 | 1.875% | 2025 | |
| €750 | 1.875% | 2025 | |
| €500 | 0.375% | 2026 | |
| €500 | 4.25% | 2026 | |
| €750 | 1.625% | 2027 | |
| €750 | 0.75% | 2028 | |
| CHF275 | 2.96% | 2028 | |
| €500 | 2.875% | 2029 | |
| CHF225 | 1.5975% | 2029 | |
| €500 | 5.00% | 2029 | |
| €550 | 2.875% | 2030 | |
| €500 | 5.125% | 2030 | |
| €500 | 1.125% | 2033 | |
| €500 | 0.00% | 2025 | |
| €700 | 2.125% | 2027 | |
| €500 | 0.50% | 2028 | |
| €500 | 0.875% | 2031 | |
| €500 | 3.00% | 2032 |
New information
- Fresenius 2024 Notes - Notice of Optional Redemption Price (PDF, 141 KB)
- Fresenius 2024 Notes - Early Redemption Notice (PDF, 55 KB)
- Fresenius 2023 Notes - Early Redemption Notice (PDF, 68 KB)
- Entry into supplemental indenture €450 million 4.000% Senior Notes due 2024 (PDF, 108 KB)
- Consent Solicitation €450 million 4.000% Senior Notes due 2024 (PDF, 105 KB)
- Notice of release of subsidiary guarantees (PDF, 20 KB)
The materiality analysis identified main non-financial topic clusters and individual topics:
The materiality process
Since 2017, we have been identifying the material topics for the Fresenius Group in a comprehensive materiality analysis in accordance with the HGB. This is carried out every two to three years, depending on possible changes in the corporate structure and operating business performance. In addition, we review the material topics annually to ensure that they are up to date. Material are those aspects that are relevant for understanding Fresenius’ business performance, results of operations, and position, as well as for understanding the effects of its business activities on non-financial aspects.
The set of topics, referred to as the long list of topics, of our latest comprehensive materiality analysis is based on previously identified topics from prior years and on a competitive analysis. We have also taken into account the requirements of the Global Reporting Initiative (GRI), the SDGs and other frameworks.
In order to determine the expectations of our external stakeholders (outside-in-analysis), we analyzed regulatory trends and legislative proposals, as well as the activities of our competitors, media coverage and the results of capital market rankings. We validated the results of this desktop analysis by the Investor Relations & Sustainability, Corporate Compliance and Corporate Communications departments. They were also compared with the materiality results of our business segments.
To be able to assess the impact of Fresenius on the non-financial aspects, we conducted a comprehensive SDG analysis. This analysis assesses the risk of negative effects and the positive impact of Fresenius on the SDGs. The results were also validated by the departments and by comparison with the materiality results of the business segments.
In order to draw up the final ranking of topics, we considered, among other things, the relevance of the topics for the business segments as well as future trends in the capital market and in legislation as corrective factors. The overall result was finalized in a closing workshop and presented it to the Group Sustainability Board.
Stakeholders and partnerships
Fresenius is involved in a diverse network of stakeholder groups. We gain valuable insights from this exchange which we use to continuously develop our quality and sustainability management as well as our reporting procedures. In 2019, we reviewed and prioritized our stakeholders: to this end, existing corporate communication channels, the requirements of sustainability ratings and rankings, and frequent inquiries from investors were evaluated.
Our main stakeholders are:
For more information on this topic see the Non-Financial Report.
Contact
If you have any questions about sustainability, please contact us:
sustainability@fresenius.com
Our contribution to the UN Sustainable Development Goals
The 17 Sustainable Development Goals (SDGs) with 169 targets, adopted by the 191 member states of the United Nations (UN) back in 2015, are the roadmap for tackling mankind´s key challenges on the path to a more sustainable world, such as poverty, discrimination and climate change. To achieve these goals, the public sector, governments and companies must work together.
As a global healthcare group, we are doing our part. Our activities might be relevant with regards to all the 17 SDGs, we see a direct link between our core business activities and our sustainability ambition and the SDGs listed below.
For a holistic overview of our sustainability related activities incl. potential risks, please refer to our Non-Financial Report 2023 and our Sustainability Highlights Report 2023.
Ensure healthy lives and promote well-being for all at all ages
For more than 100 years, we have been committed to preserving life, promoting health and improving the quality of life for our patients. As an employer, it´s our priority to create a safe and healthy working environment, and to prevent occupational diseases.
Learn more:
Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all
We are convinced that lifelong learning is essential to the personal success of our employees and the basis for the future viability of our company. This is why, we provide our employees with multiple learning opportunities, engage in the area of vocational trainings and dual study programs.
Learn more:
Ensure availability and sustainable management of water and sanitation for all
Water is one of earths' most precious resources. As a company we rely on access to clean water for providing high-quality and safe healthcare to people, and for the manufacturing of medical products. We focus on efficient water use and take measures to prevent water pollution.
Learn more:
Promote sustained, inclusive and sustainable economic growth, full and productive employment and decent work for all
We are committed to providing a fair and respectful work environment that promotes equal opportunities, along with safe and healthy working conditions and fair and appropriate wages. We expect our business partners to support our commitment to human rights and to take respective measures in their value chains.
Learn more:
Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation
We bring healthcare innovation to people. As part our of our activities we create and strengthen infrastructure in the healthcare sector. With our research & development activities we aim for innovations that increase access to healthcare, enable modernization and digitalization in healthcare and improve treatment options through research, telemedicine and artificial intelligence.
Learn more:
Take urgent action to combat climate change and its impacts
Climate action is at the core of our sustainability efforts. We work towards increasing energy efficiency and make use of renewable energy sources to continuously reduce our carbon footprint.
Learn more:
Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development
Achieving the vision behind Agenda 2030 requires concerted efforts and collaboration among multiple stakeholders at local and global levels. We engage in sector-specific and cross-sector multi-stakeholder initiatives and foster collaboration in areas such as innovation and education.
Learn more:
Contact
If you have any questions about sustainability, please contact us:
sustainability@fresenius.com
(Last updated on December 2017)
We have compiled our website very carefully and it is continually expanded and updated. Nevertheless, we assume no liability for the accuracy or completeness of the contents. We do not assume any liability for direct, indirect, material or immaterial damages that may arise from the use of the information provided on this website, except when incorrect information is published intentionally or with gross negligence. Subject to the foregoing, the use of the website is at the user’s own personal risk.
For US users: Some jurisdictions may not permit certain disclaimers of warranties, so some of the exclusions above may not apply to you. In such jurisdictions, we disclaim warranties to the fullest extent permitted by applicable law.
Business information and product information
The information on this website is non-binding and intended for general information purposes only. It is not a substitute for professional financial, medical or other specialist advice. Users should not act upon this information without first seeking appropriate professional advice. Further, we are not responsible for the content of third party texts published on this website. The individual authors are responsible for their works. We do not assume any liability for damages, which arise from the use of this information.
Releases on this website may contain forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in these releases.
Rights of use
Fresenius or its affiliates are owners of all proprietor rights attaching to the web page prepared. All texts and illustrations are covered by copyright. You may take note of the information in our websites and load them into your main memory. The use of press releases as well as documents, pictures and video footage available in the media center shall be permitted solely for editorial reporting purposes. Any further reproduction or passing on to third parties shall be excluded. No rights or licenses of any kind with respect to trademarks, copyrights, patents, etc. shall be granted to the user.
Non-commitment - applicable law
It is possible that the promotion for or the procurement of individual products, services and therapies portrayed on this website is not permissible under the legal regulations valid in individual countries outside of the European Union. The web page shall not constitute a promotion of these products, services and therapies for these countries. Please note that the products displayed on this website may not be available in all countries due to different registration status. Our local subsidiaries’ websites may include different legal provisions and your use of such websites shall be subject to the provisions provided therein.
Any legal claims or lawsuits that may arise in conjunction with this website or its use are subject to the interpretation of the laws of the Federal Republic of Germany, excluding the provisions of international private law and the UN Convention on Contracts for the International Sale of Goods.
Hyperlinks
We also offer links to third-party websites in addition to our own information. The content and design of third-party websites are beyond our control. We do not ensure that the information on third-party websites is accurate or correct. The links also represent no endorsement, support or confirmation of the contents at the linked sites. The individual authors of the linked sites are responsible for the information, opinions and facts presented on their web pages. The same is true for comments made in guest books, discussion forms and e-mail lists. We are likewise not responsible for the technical security of both the links and target pages. We are therefore not liable for any damages that occur through use of either the information contained on these hyperlinks or the use of the hyperlinks themselves.
Contact and further information
© 2000 - 2017 Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
Phone: +49 (0) 6172 608 0
Fax: +49 (0) 6172 608 2294
E-mail: pr-fre@fresenius.com
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 608-0
pr-fre@fresenius.com